SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)
SAB Biotherapeutics (SABS) reported Current Deferred Revenue of $114698.0 for Q3 2024, down 92.95% on a YoY basis from $1.6 million in Q4 2023, and little changed quarter-over-quarter from $114698.0 in Q2 2024.
SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024) Analysis & Trends
SAB Biotherapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $114698.0 in Q3 2024.
- For the quarter ending Q3 2024, Current Deferred Revenue fell 92.95% year-over-year to $114698.0; the trailing twelve-month figure through Sep 2024 stood at $114698.0 (down 92.95% YoY), and the FY2023 full-year result was $1.3 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2024 stood at $114698.0, roughly flat from $114698.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $2.9 million in Q1 2023, with the low at $100000.0 in Q4 2020.
- Historically, Current Deferred Revenue has averaged $1.1 million across 4 years, with a median of $377835.0 in 2024.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue changed 0.0% — and 2024, when it slumped 96.04%.
- SAB Biotherapeutics' Current Deferred Revenue stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then surged by 1222.41% to $1.3 million in 2023, then sank by 91.33% to $114698.0 in 2024.
- The last three Current Deferred Revenue figures came in at $114698.0 (Q3 2024), $114698.0 (Q2 2024), and $377835.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 114,698.00 |
| Jun 30, 2024 | 114,698.00 |
| Mar 31, 2024 | 377,835.00 |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 2.94 Mn |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 100,000.00 |